Liver biopsy in modern clinical practice: A pediatric point-of-view

Advances in Anatomic Pathology

Volumn 19, Issue 4, 2012, Pages 250-262

  Ovchinsky, Nadia ^a   Moreira, Roger K ^a   Lefkowitch, Jay H ^a   Lavine, Joel E ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

adolescent; children; complications; contraindications; indications; liver biopsy; pathology; pediatric

Indexed keywords

ACUTE LIVER FAILURE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOIMMUNE HEPATITIS; CHILD; CHILDHOOD DISEASE; CHOLESTASIS; CLINICAL PRACTICE; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DNA SEQUENCE; GLYCOGEN STORAGE DISEASE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTESTINAL FAILURE; INTRAHEPATIC CHOLESTASIS; LIVER BIOPSY; LIVER DISEASE; LIVER TRANSPLANTATION; LIVER TUMOR; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; POSTOPERATIVE COMPLICATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; WILSON DISEASE;

ALPHA 1-ANTITRYPSIN DEFICIENCY; BILIARY ATRESIA; BIOPSY; CHILD; CHOLANGITIS, SCLEROSING; CHOLESTASIS; CYSTIC FIBROSIS; FATTY LIVER; GLYCOGEN STORAGE DISEASE; HEMOCHROMATOSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HEPATOLENTICULAR DEGENERATION; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 84862563956     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31825c6a20     Document Type: Review

References (135)

1. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017-1044
2. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5: 898-907
3. Altman RP, Lilly JR, Greenfeld J, et al. A multivariable risk factor analysis of the portoenterostomy (Kasai) procedure for biliary atresia: twenty-five years of experience from two centers. Ann Surg. 1997;226:348-355
4. Ibrahim M, Miyano T, Ohi R, et al. Japanese Biliary Atresia Registry, 1989 to 1994. Tohoku J Exp Med. 1997;181:85-95
5. Karrer FM, Lilly JR, Stewart BA, et al. Biliary atresia registry, 1976 to 1989. J Pediatr Surg. 1990;25:1076-1081
6. McKiernan PJ. Neonatal cholestasis. Semin Neonatol. 2002;7:153-165
7. Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American society for pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2004;39:115-128
8. Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology. 1989;9:193-197
9. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195-199
10. Sorbi D, McGill DB, Thistle JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol. 2000;95:3206-3210
11. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005
12. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group. Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938
13. Gassert DJ, Garcia H, Tanaka K, et al. Corticosteroidresponsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433-2437
14. Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256: 387-396
15. Harrison RF, Hubscher SG. The spectrum of bile duct lesions in end-stage primary sclerosing cholangitis. Histopathology. 1991;19:321-327
16. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33: 544-553
17. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103:2136-2141
18. Talbot IC, Mowat AP. Liver disease in infancy. Histological features and relationship to alpha 1-antitrypsin phenotype. J Clin Pathol. 1975;28:559-563
19. Rowe SM, Miller S, Sorscher EJ. Mechanisms of disease, cystic fibrosis. N Engl J Med. 2005;352:1992-2001
20. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors and outcome. Hepatology. 2002;36:1374-1382
21. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for CF-related liver disease. Pediatrics. 1999;103:52-57
22. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302:1076-1083
23. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28(SUPPL. 1):1-13
24. Strandvik B, Hjelte L, Gabrielsson N, et al. Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol SUPPL.. 1988;143:121-124
25. Potter CJ, Fishbein M, Hammond S, et al. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr. 1997;25:32-36
26. Morotti R, Suchy F, Magid M. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis. 2011;31:3-10
27. Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2008;46:241-252
28. Clayton RJ, Iber FL, Ruebner BH, et al. Byler Disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child. 1969;117:112-124
29. Linarelli LG, Williams CN, Phillips MJ. Byler's disease: fatal intrahepatic cholestasis. J Pediatr. 1972;81:484-492
30. Jansen PLM, Strautnieks SS, Jacquemin E, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999;117:1370-1379
31. Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134:1203-1214
32. Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44:478-486
33. Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120:1448-1458
34. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis. 2001;21:551-562
35. Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis. 2011;34:593-604
36. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. American Association for Study of Liver Diseases (AASLD). Hepatology. 2008;47:2089-2111
37. Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology. 1992;15:609-615
38. Song YM, Chen MD. A single determination of liver copper concentration may misdiagnose Wilson's disease. Clin Biochem. 2000;33:589-590
39. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13:2541-2553
40. Wolsdorf JI, Holm IA, Weinstein DA. Glycogen storage disease: phenotypic, genetic, and biochemical characteristics, and therapy. Endocrinol Metab Clin. 1999;28:802-824
41. Roy A, Finegold MJ. Biopsy diagnosis of inherited liver disease. Surg Pathol Clin. 2010;3:743-768
42. Hicks J, Wartchow E,Mierau G. Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011;35:183-196
43. Panetta J, Gibson K, Kirby DM, et al. The importance of liver biopsy in the investigation of possible mitochondrial respiratory chain disease. Neuropediatrics. 2005;36:256-259
44. Knisely AS. Neonatal hemochromatosis. Adv Pediatr. 1992;39:383-403
45. Goldfischer S, Grotsky HW, Chang CH, et al. Idiopathic neonatal iron storage involving the liver, pancreas, heart, and endocrine and exocrine glands. Hepatology. 1981;1:58-64
46. Whitington PF, Malladi P. Neonatal hemochromatosis: is it an alloimmune disease? J Pediatr Gastroenterol Nutr. 2005;40:544-549
47. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis. 2007;27:243-250
48. Knisely AS, Mieli-Vergani G, Whitington PF. Neonatal hemochromatosis. Gastroenterol Clin North Am. 2003;32:877-889
49. Silver MM, Valberg LS, Cutz E, et al. Hepatic morphology and iron quantitation in perinatal hemochromatosis: comparison with a large perinatal control population, including cases with chronic liver disease. Am J Pathol. 1993;143:1312-1325
50. Udell IW, Barshes NR, Voloyiannis T, et al. Neonatal hemochromatosis: radiographical and histological signs. Liver Transplant. 2005;11:998-1000
51. Smith SR, Shneider BL, Magid M, et al. Minor salivary gland biopsy in neonatal hemochromatosis. Arch Otolaryngol Head Neck Surg. 2004;130:760-763
52. Knisely AS, O'Shea PA, Stocks JF, et al. Oropharyngeal and upper respiratory tract mucosal-gland siderosis in neonatal hemochromatosis: an approach to biopsy diagnosis. J Pediatr. 1988;113:871-874
53. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641-649
54. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203
55. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321
56. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009;50:1113-1120
57. Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 200541:1179-1197
58. Miraglia R, Luca A, Gruttadauria S. Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure. Cardiovasc Intervent Radiol. 2006;29:1008-1010
59. Laiq Z, Bishop JA, Ali SZ. Liver lesions in children and adolescents: cytopathologic analysis and clinical correlates in 44 cases. Diagn Cytopathol. 2011. doi:10.1002/dc.21587
60. Bakshi P, Srinivasan R, Rao KL, et al. Fine needle aspiration biopsy in pediatric space-occupying lesions of liver: a retrospective study evaluating its role and diagnostic efficacy. J Pediatr Surg. 2006;41:1903-1908
61. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol. 1983;14:512-537
62. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist. 2008;13:812-820
63. Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer. 2001;92:3130-3134
64. Rosenthal P. Hepatocarcinoma in viral and metabolic liver disease. J Pediatr Gastroenterol Nutr. 2008;46:370-375
65. Czauderna P, MacKinley G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology Group. J Clin Oncol. 2002;20:2798-2804
66. Hadzic N, Quaglia A, Portmann B, et al. Hepatocellular carcinoma in biliary atresia: King's College Hospital experience. J Pediatr. 2011;159:617-622
67. Bianchi L. Glycogen storage disease I and hepatocellular tumors. Eur J Pediatr. 1993;152:563-570
68. Van Spronson FJ, Bijleveldem M, van Maldegem BT, et al. Hepatocellular carcinoma in hereditary tyrosinemia type 1 despite 2 (-2 nitro 4-3 trifluoro-methyl-benzenyl) 1-3 cyclohexanedione therapy. J Pediatr Gastroenterol Nutr. 2005;40:90-93
69. Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12 y old child with PiZZ alpha-I-antitrypsin deficiency. Hepatology. 2006;43:514-521
70. Halvorsen RAJ, Garrity S, Kun C, et al. Co-existing hepatocellular carcinoma in a patient with arteriohepatic dysplasia. Abdom Imaging. 1995;20:191-196
71. Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis. 2011;31:61-70
72. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022
73. Huang GT, Sheu JC, Yang PM, et al. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol. 1996;25:334-338
74. Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol. 2001;35:254-258
75. Takamori R, Wong LL, Dang C, et al. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transplant. 2000;6:67-72
76. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43: 492-499
77. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplant. 2004;10:1240-1247
78. Abraham SC, Freese DK, Ishitani MB, et al. Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol. 2008;32:1479-1488
79. Sundaram SS, Melin-Aldana H, Neighbors K, et al. Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients. Liver Transplant. 2006;12: 58-64
80. Gouw AS, van den Heuvel MC, van den Berg AP, et al. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. Transplantation. 2002;73:243-247
81. Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010; 52:2192-2205
82. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes in 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;759-768
83. Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr. 1999;29:163-170
84. Woynarowski M, Cielecka-Kuszyk J, Kauzyń ski A, et al. Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment. World J Gastroenterol. 2006;12:1713-1717
85. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114:988-995
86. Hom X, Little NR, Gardner SD, et al. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B. Pediatr Infect Dis J. 2004;23:441-445
87. Guido M, Bortolotti F. Chronic viral hepatitis in children: any role for the pathologist? Gut. 2008;57:873-877
88. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology. 2006;130(2 SUPPL. 1):S70-S77
89. Tulikoura K. Huikuri morphological fatty changes and function of the liver, serum free fatty acids and triglycerides during parenteral nutrition. Scand J Gastroenterol. 1982;17: 177-185
90. Beath SV, Needham SJ, Kelly DA, et al. Clinical features and prognosis of children assessed for isolated small bowel (ISBTx) or combined small bowel and liver transplantation. J Pediatr Surg. 1997;32:459-461
91. Colomb BV, Goulet O, DC Rambau, et al. Long-term parenteral nutrition in children; liver and gallbladder disease. Transplant Proc. 1992;24:1054-1055
92. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28:323-331
93. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38: 1449-1457
94. Hahm GK, Niemann TH, Lucas JG, et al. The value of second opinion in gastrointestinal and liver pathology. Arch Pathol Lab Med. 2001;125:736-739
95. Brough AJ, Bernstein J. Conjugated hyperbilirubinemia in early infancy: a reassessment of liver biopsy. Hum Pathol. 1974;5:507-516
96. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1 pt 1):15-20
97. Bedossa P, Poynard T, Naveau S, et al. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res. 1988;12:173-178
98. Younossi ZM, Boparai N, Gramlich T, et al. Agreement in pathologic interpretation of liver biopsy specimens in posttransplant Hepatitis C infection. Arch Pathol Lab Med. 1999;123:143-145
99. Smith CI, Grau JE. The effect of ultrasonography on the performance of routine liver biopsy. Hepatology. 1995;22: 384A
100. Riley TR. How often does ultrasound marking change the liver biopsy site? Am J Gastroenterol. 1996;91:1292-1296
101. Lindor KD, Jorgensen RA, Rakela J, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology. 1996;23:1079-1083
102. Stowe MA, Mayberry JF. An audit of ultrasound guided liver biopsies: a need for evidence-based practice. Hepatogastroenterology. 1996;23:1079-1083
103. McAfee JH, Keeffe EB, Lee RG, et al. Transjugular liver biopsy. Hepatology. 1992;15:726-732
104. Lebrec D, Goldfarb G, Degott C, et al. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology. 1992;83:338-340
105. Tobin MV, Gilmore IT. Plugged liver biopsy in patients with impaired coagulation. Dig Dis Sci. 1989;34:13-15
106. Riley SA, Ellis WR, Irving HC, et al. Percutaneous liver biopsy with plugging of needle track: a safe method for use in patients with impaired coagulation. Lancet. 1984;2:436
107. Sawyer AM, McCormick PA, Tennyson GS, et al. A comparison of transjugular and plugged-percutaneous liver biopsy in patients with impaired coagulation. J Hepatol. 1993;17:81-85
108. Firpi RJ, Soldevila-Pico C, Abdelmalek MF, et al. Short recovery after percutaneous liver biopsy: should we change our current practices? Clin Gastroenterol Hepatol. 2005;3: 926-929
109. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396-1400
110. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2: 165-173
111. Liu C, Aronow BJ, Jegga AG, et al. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology. 2007;132:119-126
112. Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544-2555
113. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007;46:297-306
114. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010;139:1567-1576
115. Nguyen D, Talwalker JA. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:2107-2110
116. Nobili V, Vizzuti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48:442-448
117. De Lédinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr. 2007;45:443-450
118. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43(2 SUPPL. 1):S113-S120
119. Rustogi R, Horowitz J, Harmath C. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging. 2012;35:1356-1364
120. Nobili V, Pinzani M. Paediatric nonalcoholic fatty liver disease. Gut. 2010;59:561-564
121. Pacifico L, Celestre M, Anania C, et al. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr. 2007;96:542-547
122. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;50: 1072-1078
123. Imbert-Bismut F, Messous D, Thibault V, et al. Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;42: 323-333
124. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010; 10:103
125. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006;101:547-555
126. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455-460
127. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009;136:160-167
128. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078
129. Seidel N, Volkmann X, Lä nger F, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113-120
130. Valva P, de Matteo E, Galappo MC, et al. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol. 2010;82:949-957
131. Joka D, Wahl K, Moeller S, et al. Prospective biopsycontrolled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012;55:455-464
132. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809
133. Bell LN, Theodorakis JL, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010;51:111-120
134. Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;26:847-858
135. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328-335